This Good Clinical Practice aligned, double-blind, placebo-controlled, randomized clinical trial will be implemented by an experienced, transdisciplinary, and productive team of investigators from two sites to enhance the diversity of the study sample and generalizability of results. The investigators will enroll healthy pregnant women (n=312) with a recent history of smoking and a desire to remain abstinent after childbirth. Using a randomized controlled trial design, participants will be randomized into one of two assignments: (1) Prog, (2) Placebo. Using procedures successfully implemented in our pilot study, participants will begin the 13-week study medication four days after childbirth. Participants will be followed for nine months with home/clinic visits, self-administered surveys, and self-collection of dried blood spots to measure hormones and smoking-related biomarkers.
The investigators aim to address the following specific aims:~Determine the efficacy of Prog in preventing postpartum smoking relapse and reducing smoking relapse risk factors.~Examine the effects of this maternal smoking intervention on infant health.~Examine racial and ethnic differences in intervention outcomes.